Collaborating on veterinary vaccines

Boehringer Ingelheim Vetmedica is a global, research-driven pharmaceutical company which is emerging as a new global leader in veterinary medicines.

Driven by new technology and approaches, veterinary medicine will see a wave of innovation in the coming years, to the benefit of veterinarians, animals and animal owners, and Boehringer Ingelheim will be at the vanguard of this development.

The company is pursuing new models of collaboration between different stakeholders, as this will be a key driver for innovation. It operates under the belief that partnerships drive innovation, and strives to be the partner of choice for identifying and developing novel solutions for animal care.

How can companies collaborate on innovation?

This booklet reflects on the opportunities for collaboration presented by the World Vaccine Congress Europe 2017, which took place in October 2017. The congress covered a broad range of subjects related to vaccines, including:

  • Bioprocessing, delivery and manufacturing
  • Emerging and re-emerging diseases
  • Veterinary medicine;
  • Preclinical validation to clinical trials;
  • Immune profiling; and
  • Adjuvant technologies and immunotherapies.

Following this, Boehringer Ingelheim Vetmedica’s Dr Randolph Seidler analyses some of the emerging trends in veterinary vaccines. He explains the role that vaccines play in ensuring animals remain healthy, and warns that many clinically relevant diseases lack satisfactory vaccine solutions.

How are vaccines developed?

To address the challenges of a lack of vaccines, Boehringer Ingelheim continues to innovate and drive towards new and better solutions, relying on recent advances in the understanding of immunogenic and protective antigens of pathogens, and the ability to produce recombinant proteins at high quality cost-effectively.

The article also reviews the current state of vector-based vaccines and vaccines using targeted deletions and modifications, the role of vaccines in the fight against antimicrobial resistance, and the role of collaboration, partnership and strategic alliances in innovation.

The booklet concludes with a piece by Andrea Rappagliosi, the president of Vaccines Europe, who offers his thoughts on how the EU can strengthen its approach to communicable diseases through a more effective vaccination programme.

LEAVE A REPLY

Please enter your comment!
Please enter your name here